Disease · MONDO_0005210

uterine corpus sarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. uterine corpus sarcoma. Diseases, record MONDO_0005210. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005210

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: uterine corpus sarcoma; Open Targets
Open Targets ID: MONDO_0005210; Open Targets
Other names: body of uterus sarcoma, corpus uteri sarcoma, sarcoma of body of uterus, sarcoma of corpus uteri, sarcoma of the body of uterus, sarcoma of the corpus uteri, sarcoma of the uterine body, sarcoma of the uterine corpus, sarcoma of uterine body, sarcoma of uterine corpus, sarcoma of uterus, uterine body sarcoma, uterine sarcoma, uterus sarcoma; Open Targets
Disease Ontology: DOID:5165; Disease Ontology
NCI Thesaurus: C6339; NCI Thesaurus
Orphanet: ORPHA:213620; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 21 drugs, from ClinicalTrials.gov; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BENMELSTOBART	CHEMBL5315042	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CATEQUENTINIB HYDROCHLORIDE	CHEMBL5314570	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets44

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 44

See all 44 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03509207	Vorinostat (SAHA) in Uterine Sarcoma	Phase 2	3	2020-07-27	Leiomyosarcoma, Endometrial Stromal Tumors, Carcinosarcomas Uterine	VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00162721	The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas	Phase 3	270		Uterine Sarcoma	CISPLATIN, DOXORUBICIN, IFOSFAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05481645	Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.	Phase 2	71		Advanced Endometrial Cancer, Sarcoma of Uterus	BENMELSTOBART, CARBOPLATIN, CATEQUENTINIB HYDROCHLORIDE, DOCETAXEL, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00032162	Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer	Phase 1/2	63		Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma	CARBOPLATIN, DOXORUBICIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01979393	IRCI Gynae Sarcomas, High Grade Uterine Sarcoma	Phase 2	58		Uterine Sarcoma	CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT03192059	Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer	Phase 2	43		Cervical Cancer, Endometrial Cancer, Uterine Cancer	ASPIRIN, CYCLOPHOSPHAMIDE, ERGOCALCIFEROL, LANSOPRAZOLE, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00815945	Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors	Phase 2	41		Mesenchymal Tumor, Carcinosarcoma, Leiomyosarcoma	CARBOPLATIN, DOXORUBICIN	Its record names the disease	ClinicalTrials.gov
NCT05162755	S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers	Phase 1	41		Solid Tumor	SYM-021	Its record names the disease	ClinicalTrials.gov
NCT00002993	Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus	Phase 2	30		Sarcoma	CISPLATIN, DOXORUBICIN, MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT07467772	Ph 2 Elacestrant in ER Positive Uterine Sarcomas	Phase 2	30		Uterine Sarcoma, Uterine Leiomyosarcoma, Endometrial Stromal Sarcoma, ESS, Perivascular Epithelioid Cell Tumors, Uterine Adenosarcoma, Uterine PEComa, Estrogen Receptor Positive Tumor, uLMS	ELACESTRANT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
17910981	RESULT	1	PubMed
12051882	RESULT	1	PubMed
42253973	DERIVED	1	PubMed
42103356	DERIVED	1	PubMed
39515198	DERIVED	1	PubMed
35960332	DERIVED	1	PubMed
34009140	DERIVED	1	PubMed
32546554	DERIVED	1	PubMed
31138229	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005210

GET https://conductscience.org/api/diseases/v1/MONDO_0005210/drugs?page=2

API reference For AI assistants